Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | Climb Bio (NASDAQ:CLYM) Releases Earnings Results, Beats Estimates By $0.02 EPS | 1 | MarketBeat | ||
25.03. | Climb Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
CLIMB BIO Aktie jetzt für 0€ handeln | |||||
25.03. | Climb Bio, Inc.: Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates | 486 | GlobeNewswire (Europe) | Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus... ► Artikel lesen | |
25.03. | Climb Bio, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
20.03. | Climb Bio SVP Emily Pimblett verkauft Aktien im Wert von 1.570 US-Dollar | 2 | Investing.com Deutsch | ||
24.02. | Climb Bio, Inc.: Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer | 308 | GlobeNewswire (Europe) | WELLESLEY HILLS, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) announced today the appointment of Perrin Wilson, Ph.D. as Chief Business Officer. Dr. Wilson is an accomplished... ► Artikel lesen | |
10.01. | Climb Bio enters licensing deal with Mabworks for CLYM116 development | 1 | Pharmaceutical Technology | ||
10.01. | Climb Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
09.01. | Climb Bio, Inc.: Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy | 170 | GlobeNewswire (Europe) | Transaction Expands Climb Bio's Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated Diseases New Program is a Highly Potent, Fc-engineered anti-APRIL Monoclonal Antibody Specifically... ► Artikel lesen | |
19.12.24 | Climb Bio, Inc.: Climb Bio to be Added to the Nasdaq Biotechnology Index | 103 | GlobeNewswire (Europe) | WELLESLEY HILLS, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- December 19, 2024 - Climb Bio, Inc. (Nasdaq: CLYM) today announced that the company will be added to the NASDAQ Biotech Index (Nasdaq: NBI)... ► Artikel lesen | |
04.12.24 | Leerink Partnrs Comments on Climb Bio FY2024 Earnings | 2 | MarketBeat | ||
11.11.24 | Climb Bio names Douglas Williams as chair | 1 | Seeking Alpha | ||
11.11.24 | Climb Bio, Inc.: Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board | 1 | GlobeNewswire (USA) | ||
24.10.24 | Woodforest Acceptance Solutions Partners With Clym to Enhance Website Accessibility and Compliance With Consumer Privacy Regulations | 288 | ACCESS Newswire | Woodforest Acceptance Solutions Partners with Clym to Enhance Merchants' Compliance and Website Accessibility, Empowering Businesses to Navigate Digital Regulations Seamlessly THE WOODLANDS, TX / ACCESSWIRE... ► Artikel lesen | |
15.10.24 | Climb Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
15.10.24 | Climb Bio, Inc.: Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event | 1 | GlobeNewswire (USA) | ||
11.10.24 | Climb Bio präsentiert Studie zur Behandlung von Nierenerkrankungen | - | Investing.com Deutsch | ||
11.10.24 | Climb Bio to present kidney disease treatment study | 1 | Investing.com | ||
11.10.24 | Climb Bio, Inc.: Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024 | 3 | GlobeNewswire (USA) | ||
04.10.24 | Climb Bio, Inc.: Climb Bio to Present at William Blair's Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19 | 1 | GlobeNewswire (USA) |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 84,90 | +2,97 % | EQS-News: CureVac erhält positive Entscheidung zur Patentgültigkeit vom Europäischen Patentamt im Rechtsstreit mit BioNTech SE | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Patent
CureVac erhält positive Entscheidung zur Patentgültigkeit vom Europäischen Patentamt im Rechtsstreit mit BioNTech SE
27.03.2025... ► Artikel lesen | |
CUREVAC | 2,566 | -0,62 % | UNGLAUBLICHE Sondermeldung bei CureVac Aktie: DAS erwischt Anleger heute eiskalt. Dringend lesen und reagieren! | ||
MODERNA | 25,400 | -3,09 % | Moderna-Aktie leicht im Minus (29,9070 €) | Der Anteilsschein von Moderna notiert heute ein wenig leichter. Der jüngste Kurs betrug 32,24 US-Dollar. Für der Anteilsschein von Moderna steht gegenwärtig ein Abschlag von 4,13 Prozent zu Buche. Die... ► Artikel lesen | |
REGENERON PHARMACEUTICALS | 574,80 | -2,01 % | Regeneron Pharmaceuticals (NASDAQ:REGN) Hits New 52-Week Low on Analyst Downgrade | ||
QIAGEN | 37,135 | +1,25 % | Biotech Report: Sektor unter Druck - Evotec verlieren, Qiagen behauptet | (shareribs.com) Frankfurt / New York 26.03.2025 - Biotechwerte tendierten im deutschen Handel schwächer, lediglich 4SC konnte leichte Kursgewinne verbuchen. An der Wall Street rutschte der Sektor ab.... ► Artikel lesen | |
TEMPUS AI | 46,810 | -2,96 % | Tempus AI Surges 43% YTD: Is it the Right Time to Invest in the Stock? | ||
BIOAFFINITY TECHNOLOGIES | 1,100 | +300,00 % | RedChip Companies, Inc.: bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | ORLANDO, FLORIDA / ACCESS Newswire / March 28, 2025 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (Nasdaq:BIAF) and Can-Fite BioPharma Ltd. (NYSE American:CANF) on the... ► Artikel lesen | |
MINERALYS THERAPEUTICS | 13,940 | -12,38 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's ... | - Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile... ► Artikel lesen | |
EVOTEC | 6,125 | +1,07 % | Evotec-Aktie: Crash auf 4 Euro voraus? Behält die Deutsche Bank Recht mit Ihrem Kursziel? | © Foto: Symbolbild von pina messina auf UnsplashKooperationen mit Pharma-Giganten, Hightech-Forschung und trotzdem bewegt sich die Evotec-Aktie nicht richtig nach oben. Die Deutsche Bank warnte vor... ► Artikel lesen | |
BEAM THERAPEUTICS | 17,610 | -9,90 % | Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration | U.S. IND Represents Regulatory Clearance For BEAM-302 Spanning Six Countries and Second Open IND for a Beam In Vivo Base Editing Program in the U.S. CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
BB BIOTECH | 31,900 | +0,31 % | BB Biotech Aktie: Gibt es jetzt Probleme? | Die BB Biotech AG kämpft aktuell mit einem erheblichen Wertverlust. Die Aktie notiert bei 31,85 CHF und hat innerhalb der letzten Woche einen Rückgang von 8,08% verzeichnet. Im Monatsvergleich fällt... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,065 | -4,16 % | Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today | ||
SPRINGWORKS THERAPEUTICS | 41,490 | -6,02 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates | - Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively - - Received FDA approval of GOMEKLI (mirdametinib)... ► Artikel lesen | |
IMMUNOVANT | 15,315 | -10,33 % | Immunovant Inc.: Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies | Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a... ► Artikel lesen | |
NUVALENT | 68,80 | -2,93 % | Nuvalent-Entwicklungschefin verkauft Aktien im Wert von 292.468 US-Dollar |